Gene therapy: Advances and limitations
Nancy L. Ascher – 1 September 1996 – Recombinant adenovirus vectors are efficient at transferring genes into somatic tissues but are limited for use in clinical gene therapy by immunologic factors that result in the rapid loss of gene expression and inhibit secondary gene transfer. This study demonstrates that systemic coadministration of recombinant adenovirus with soluble CTLA4lg, which is known to block co‐stimulatory signals between T cells and antigen presenting cells, leads to persistent adenovirus gene expression in mice without long‐term immunosuppression.